Apoptotic Potential of Artemsia sieberia Besser (Asteraceae) Fraction against Human Cancer Cell Lines
Abstract
Purpose: To investigate the anti-proliferative and apoptotic activity of crude and dichloromethane fraction of A. sieberi against seven cancer cell lines (Colo20, HCT116, DLD, MCF7, Jurkat, HepG2 and L929).
Methods: A. sieberi was extracted with methanol and further purification was carried out using liquidliquid extraction with hexane, dichloromethane and ethyl acetate. Each extract was assayed for cytotoxic potential against cancer cell lines using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide (MTT) assay. The morphology of the HepG2 cell nucleus was investigated by Hoechst 33342, DNA-binding dye. A Tali™ image-based cytometer was used to assess cell viability, death and apoptosis using annexin-v /pi (propidium iodide). A chromatographic fingerprint was constructed using high performance liquid chromatography (HPLC).
Results: The most effective anticancer activity of the unrefined methanol extract was against HepG2 cell lines (LC50 = 161.5 μg/mL). The hexane and ethyl acetate fractions showed no antiproliferative activity. The dichloromethane fraction displayed higher cytotoxic activity (LC50 = 61.75 μg/mL) and also repressed the migration of the cells. About 50 % of HepG2 cells were apoptotic when treated for 24 h with the dichloromethane fraction at the concentration of 120 μg/mL
Conclusion: A. sieberi possesses apoptotic activity and inhibited the migration of the HepG2 cell lines.
Keywords: Artemsia Sieberia, Apoptosiss, Cytotoxicity, Hoescht staining, HepG2 cell lines
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
